PTC Q2 Profit Rises, Lifts FY21 Outlook

PTC (PMTC) Wednesday reported second-quarter net income of $109.3 million or $0.92 per share, up from $7.2 million or $0.06 per share last year.

Adjusted earnings for the quarter were $1.08 per share, up from $0.59 per share last year.

Revenues for the quarter grew 28% to $461.8 million from $359.6 million last year, driven primarily by strong execution, as well as the impact of up-front license revenue recognition under ASC 606, and a modest contribution from Arena.

Analysts polled by Thomson Reuters expected earnings of $0.70 per share on revenues of $416.19 million. Analysts' estimates typically exclude one-time items.

Looking forward to full year 2021, the company now expects adjusted earnings of $3.18 to $3.39 per share and revenues of $1.71 billion to $1.74 billion. Analysts currently estimate earnings of $3.16 per share on revenues of $1.71 billion.

Previously, the company expected adjusted earnings of $3.05 to $3.25 per share on revenues of $1.69 billion to $1.73 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Samsung Electronics Co Ltd (SMSN.L, SSNNF.OB, SSNLF.OB) reported a profit for the second-quarter that climbed 72.18 percent from the previous year, reflecting higher-than-expected chip prices and continued consumer demand for electronics during the pandemic. Quarterly revenue grew 20.21 percent from the prior year. Flavor maker McCormick & Co., Inc. is recalling certain McCormick and Frank's brand seasoning products citing possible salmonella risk, the U.S. Food and Drug Administration said. The recall involves McCormick Perfect Pinch Italian Seasoning, McCormick Culinary Italian Seasoning and Frank's RedHot Buffalo Ranch Seasoning. Drug major Pfizer Inc. raised Wednesday its outlook for fiscal 2021 earnings and revenues following strong second quarter results that exceeded market estimates. According to the company, the upward revision in full-year outlook, for the second quarter in a row, reflects its updated expectations for contributions to 2021 performance from both BNT162b2, the Pfizer-BioNTech SE COVID-19 vaccine.
Follow RTT